Systemic Vasculitis: Clinical Trials

5 trials for Systemic Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Terminated 5
Phase 21Terminated 1

Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids - Wegeners Granulomatosis
Phase 3TerminatedNordic Pharma SAS42011-11-012015-05-29
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
depot leuprolide acetate 3.75 mg, Placebo - Lupus Erythematosus, Systemic, Systemic Vasculitis
Phase 3TerminatedJoseph Mccune142011-05-012017-06-27
IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Cyclophosphamide, Mycophenolate mofetil, Azathioprine - ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris1602003-05-012006-04-10
Intravenous Immunoglobulin After Relapse in Vasculitis
Intravenous immunoglobulins (human immunoglobulins G) - ANCA + Vasculitides Relapsing Either Under Corticosteroid, and Immunosuppressant Therapies or After One Year
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris402001-03-012006-05-22
Plasma Exchange for Renal Vasculitis
Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone - Wegener's Granulomatosis, Microscopic Polyangiitis
Phase 2 / Phase 3TerminatedCambridge University Hospitals NHS Foundation Trust1501995-03-012011-08-03

Narrower conditions

Granulomatosis with Polyangiitis (2)  ·  Microscopic Polyangiitis (2)  ·  Recurrence (2)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Vasculitis (1)

Broader conditions

Autoimmune Diseases (5)  ·  Cardiovascular Diseases (5)  ·  Immune System Diseases (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Vascular Diseases (5)  ·  Skin Diseases (4)  ·  Skin Diseases, Vascular (4)  ·  Vasculitis (4)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Cerebral Small Vessel Diseases (2)  ·  Cerebrovascular Disorders (2)  ·  Disease Attributes (2)

Interventions

Azathioprine (2)  ·  Cyclophosphamide (1)  ·  Glucocorticoids (1)  ·  Immunoglobulins, Intravenous (1)  ·  Leuprolide (1)  ·  Methotrexate (1)  ·  Methylprednisolone (1)  ·  Mycophenolic Acid (1)  ·  Plasma Exchange (1)  ·  Prednisone (1)  ·  gusperimus (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (2)  ·  Cambridge University Hospitals NHS Foundation Trust (1)  ·  Joseph Mccune (1)  ·  Nordic Pharma SAS (1)

Countries

France (2)  ·  United Kingdom (2)  ·  Czechia (1)  ·  United States (1)

Top investigators

David Jayne, MD (1)  ·  Niels Rasmussen, MD (1)  ·  William J McCune, M.D. (1)

Results publications

PMID 18163506, PMID 21060104, PMID 23615499, PMID 28592297

NIH funding

R01HD066139 (1)